Precigen Inc (PGEN)
🔔 Watch stock
Appears in These Scanners
This stock currently matches 17 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Quality & Screener
AI Rating
NeutralPrecigen ist ein Gen-/Immuntherapie-Unternehmen; die geprüften SEC-Berichte belegen keinen wesentlichen KI-Bezug — künstliche Intelligenz taucht nur als allgemeine regulatorische Floskel auf, weder als Umsatzquelle noch als konkretes operatives Werkzeug oder Geschäftsrisiko.
View the full file — quotes, sources, reviewed filings
„The rapid evolution of AI will require the application of significant resources to design, develop, test and maintain such systems to help ensure that AI is implemented in accordance with applicable law and regulation and in a socially responsible manner and to minimize any real or perceived unintended harmful impacts."
Die rasche Entwicklung der KI wird den Einsatz erheblicher Ressourcen erfordern, um solche Systeme zu entwerfen, zu entwickeln, zu testen und zu warten und so sicherzustellen, dass KI im Einklang mit geltendem Recht und sozial verantwortlich eingesetzt wird und reale oder wahrgenommene unbeabsichtigte Schäden minimiert werden.
„Our commercial product, Papzimeos (zopapogene imadenovec-drba, PRGN-2012), is the first and only US Food and Drug Administration ("FDA") approved therapy for the treatment of adults with recurrent respiratory papillomatosis ("RRP")."
Unser kommerzielles Produkt Papzimeos (zopapogene imadenovec-drba, PRGN-2012) ist die erste und einzige von der US-Arzneimittelbehörde FDA zugelassene Therapie zur Behandlung erwachsener Patienten mit rezidivierender respiratorischer Papillomatose (RRP).
Filings Reviewed: 10-K 2026-03-25 · 10-K 2025-03-19 · 10-Q 2026-05-13 · 10-Q 2025-11-13 · 10-Q 2025-08-12 · 10-Q 2025-05-14
Rated on July 10, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.07 | – | 1 | -3.10 | -1,657.70 | -8 | -9 |
| 2025: Q1 | -0.18 | – | 1 | 25.90 | -4,038.30 | -16 | -17 |
| 2025: Q2 | -0.09 | – | 1 | 19.40 | -3,112.40 | -19 | -20 |
| 2025: Q3 | -0.49 | – | 3 | 206.60 | -5,008.40 | -29 | -30 |
| 2025: Q4 | -0.08 | – | 5 | 283.60 | -514.90 | -24 | -24 |
| 2026: Q1 | -0.03 | – | 23 | 1,633.90 | -34.10 | -44 | -44 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Precigen, Inc., ein biopharmazeutisches Unternehmen in der Entdeckungs- und klinischen Phase, entwickelt Gen- und Zelltherapien mit Präzisionstechnologie zur gezielten Behandlung von Krankheiten in den Bereichen Immunonkologie, Autoimmunerkrankungen und Infektionskrankheiten.
| Employees | 160 |
|---|---|
| Headquarters | Germantown, MD |
| Website | precigen.com |
| IPO Date | 8. Aug 2013 |
| Next Earnings | 11. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Randal J. Kirk J.D. | Executive Chairman | 1953 |
| Helen Sabzevari MPH, Ph.D. | President, CEO & Director | 1962 |
| Harry Thomasian Jr. | Chief Financial Officer | 1962 |
| Rutul R. Shah | Chief Operating Officer | 1981 |
| Donald P. Lehr J.D., Ph.D. | Chief Legal Officer & Corporate Secretary | 1975 |
| Phil Tennant | Chief Commercial Officer | 1970 |
| Steven M. Harasym | VP & Head of Investor Relations | – |
| Douglas E. Brough Ph.D. | Senior VP & Head of Research | 1955 |
| Bryan T. Butman Ph.D. | Senior VP & Head of CMC | 1953 |
| Amy R. Lankford Ph.D. | Senior VP & Head of Clinical Operations and Regulatory Affairs | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.